Effects of valproate on sexual development;Efectos del ácido valproico sobre el desarrollo sexual

Anales de Pediatria

Volumn 58, Issue 5, 2003, Pages 443-448

  Balaguer Martinez J V ^b   Lopez Garcia M J ^a   Andres Celma M ^b   Contell Villagrasa, A ^b   Castello Pomares M L ^b  

^a HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^b NONE

Author keywords

Body weight; Hyperandrogenism; Puberty; Testosterone; Valproic acid

Indexed keywords

ANDROSTENEDIONE; ESTRADIOL; FOLLITROPIN; INSULIN; LUTEINIZING HORMONE; PRASTERONE; TESTOSTERONE; VALPROIC ACID;

ADOLESCENT; ANTHROPOMETRY; ARTICLE; BODY MASS; BODY WEIGHT; BONE AGE; CHILD; CLINICAL ARTICLE; EPILEPSY; FEMALE; HIRSUTISM; HUMAN; HYPERANDROGENISM; MALE; OVARY POLYCYSTIC DISEASE; PUBERTY; SEXUAL DEVELOPMENT; SEXUAL MATURATION; WEIGHT GAIN;

EID: 0037834678     PISSN: 16954033     EISSN: None     Source Type: Journal    
DOI: 10.1157/13046528     Document Type: Article

References (32)

1. Blaise FD. Valproic acid: Clinical use. En: Levy R, Mattson R, Meldrum B, editors. Antiepileptic drugs. Philadelphia: Lippincott-Raven, 1996; p. 633-9.
2. Elices E, Arroyo S. Acido valproico. En: Cruz GA, Vadillo FJ, editores. Efectos adversos e interacciones de los fármacos antiepilépticos. Madrid: Janssen-Cilag, 2000; p. 65-81.
3. Dreifuss F. Valproic acid: Toxicity. En: Levy R, Mattson R, Meldrum B, editors. Antiepileptic drugs. Philadelphia: Lippincott-Raven, 1996; p. 641-8.
4. Dinesen H, Gram L, Andersen T, Dam M. Weight gain during treatment with valproate. Acta Neurol Scand 1984;70:65-9.
5. Corman CL, Leung NM, Guberman AH. Weight gain in epileptic patients during treatment with valproic acid: A retrospective study. Can J Neurol Sci 1997;24:240-4.
6. Murialdo G, Galimberti CA, Gianelli MV, Rollero A, Polleri A, Copello F, et al. Effects of valproate, phenobarbital and carbamazepine on sex steroid setup in women with epilepsy. Clin Neuropharmacol 1998;21:52-8.
7. Biton V, Mirza W, Montouris G, Vuong A, Hammer AE, Barret PS. Weight change associated with valproate and lamotrigine monotherapy in patients with epilepsy. Neurology 2001;23;56: 172-7.
8. Breum L, Astrup A, Gram L, Andersen T, Stokholm KH, Christensen NJ, et al. Metabolic changes during treatment with valproate in humans: Implication for untoward weight gain. Metabolism 1992;41:666-70.
9. Egger J, Brett EM. Effects of sodium valproate in 100 children with special reference to weight. BMJ 1981;283:577-81.
10. Novak GP, Maytal J, Alshansky A, Eviatar L, Sy-Kho R, Siddique Q. Risk of excesive weight gain in epileptic children treated with valproate. J Child Neurol 1999;14:490-5.
11. Demir E, Aysun S. Weight gain associated with valproate in childhood. Pediatr Neurol 2000;22:361-4.
12. Rattya J, Vainionpaa L, Knip M, Lanning P, Isojarvi J. The effects of valproate, carbamazepine, and oxcarbazepine on growth and sexual maturation. Pediatrics 1999;103:588-93.
13. Isojarvi J, Laatikainen T, Knip M, Pakarinen A, Juntunen K, Myllyla V. Obesity and endocrine disorders in women taking valproate for epilepsy. Ann Neurol 1996;39:579-84.
14. Herzog AG, Seibel MM, Schomer DL, Vaitukaitis JL, Geschwind N. Reproductive endocrine disorders in men with partial seizures of temporal lobe origin. Arch Neurol 1986;43:347-50.
15. Herzog AG, Seibel MM, Schomer DL, Vaitukaitis JL, Geschwind N. Reproductive endocrine disorders in women with partial seizures of temporal lobe origin. Arch Neurol 1986;43:341-6.
16. Bilo L, Meo R, Nappi C. Reproductive endocrine disorders in women with primary generalized epilepsy. Epilepsia 1988;29: 612-9.
17. Isojarvi J, Laatikainen T, Pakarinen A, Juntunen K, Myllyla V. Polycystic ovaries and hyperandrogenism in women taking valproate for epilepsy. N Engl J Med 1993;329:1383-8.
18. Isojarvi J, Rattya J, Myllyla V, Knip M, Koivunen R, Pakarinen A, et al. Valproate, lamotrigine, and insulin-mediated risk in women with epilepsy. Ann Neurol 1998;43:446-51.
19. Rattya J, Pakarinen A, Knip M, Repo-outakoski M, Myllyla VV, Isojarvi J. Early hormonal changes during valproate or carbamazepine treatment: A 3-month study. Neurology 2001;14: 440-4.
20. Chappell KA, Markowitz JS, Jackson CW. Is valproate pharmacotherapy associated with poycystic ovaries? Ann Pharmacother 1999;33:1211-6.
21. Isojarvi J, Tapanainen J. Valproate, hyperandrogenism, and poycystic ovaries: A report of 3 cases. Arch Neurol 2000;57: 1064-8.
22. Vainionpaa L, Rattya J, Knip M, Tapanainen J, Pakarinen A, Lanning P, et al. Valproate-induced hyperandrogenism during pubertal maduration in girls with epilepsy. Ann Neurol 1999; 45:444-50.
23. Isojarvi J, Pakarinen AJ, Ylipalosaari PJ, Myllyla VV. Serum hormones in male epileptic patients receiving anticonvulsant medication. Arch Neurol 1990;47:670-6.
24. Rattya J, Turkka J, Pakarinen AJ, Knip M, Kotila M, Lukkarinen O, et al. Reproductive effects of valproate, carbamacepine, and oxcarbacepine in men with epilepsy. Neurology 2000;56:31-6.
25. Tanner JM, Whitehouse RH. Clinical longitudinal standards for height, weight velocity and stages of puberty. Arch Dis Child 1976;51:170-82.
26. Ferriman D, Gallway JD. Clinical assessment of body hair growth in women. J Clin Endocrinol Metab 1961;21:1440-7.
27. Greulich WW, Pyle SI. Radiographic atlas of skeletal development of the hand and wrist. Stanford: Stanford University Press, 1959.
28. Adams J, Polson DW, Franks S. Prevalence of polycystic ovaries in women with anovulation and idiopatic hirsutism. BMJ 1986;293:355-8.
29. Kurowski H, Gospe S, Zeman F, Grivetti L. Nutritional factors and anticonvulsionant therapies: Effect on growth in children with epilepsy. Am J Clin Nutr 1993;58:858-61.
30. Easter D, O'Bryan CG, Verity C. Weight gain with valproate or carbamazepine: A reppraisal. Seizure 1997;6:121-5.
31. Penry JK, Dean JC. The scope and use of valproate in epilepsy. J Clin Psychiatry 1989;50;17-22.
32. Vela A, Rica I, Martul P. Valoración clínica y hormonal del tratamiento con valproato en mujeres durante el periodo peripuberal. XX congreso de la Sociedad Española de Endocrinología Pediátrica. An Esp Pediatr 1998;48 (Supl IlI):90.